new glp 1 agonist novo nordisk GLP-1 analogs, trend in obesity treatment, become even more effective < Pharma < Article Wegovy for the Treatment of – Novo Nordisk Drops Hims &

Supporting these findings, a 12-week RCT by Navarro-Lpez et al

Effects of baicalin on diabetic neuropathic pain involving transient receptor potential vanilloid 1 in the dorsal root ganglia of rats

Tsaousidou E, Paeger L, Belgardt BF, Pal M, Wunderlich CM, Brnneke H, Collienne U, Hampel B, Wunderlich FT, Schmidt-Supprian M, Kloppenburg P, Brning JC (2014) Distinct roles for JNK and IKK activation in Agouti-related peptide neurons in the development of obesity and insulin resistance

WHO expands essential medicines list to include GLP-1 agonists and Cystic Fibrosis therapies Key Takeaways: The World Health Organization (WHO) has added GLP-1 receptor agonists, rapid-acting insulin analogues, and innovative cancer therapies to its 2025 Essential Medicines Lists (EMLs), signalling their importance in global diabetes and oncology care